PPARA and metabolic dysfunction-associated steatotic liver disease: Currently, there is no FDA-approved treatment for NAFLD or NASH, but PPAR agonists improve metabolic dysfunction, inflammation, and oxidative stress which are associated with these liver diseases [61].